

Curriculum Vitae

Jamie A. Cesaretti, MD, MS

7017 A.C. Skinner Parkway

Jacksonville, FL 32256

(904) 520-6800 office

(904) 520-6801 office fax

Hospital Appointments/Affiliations

7/2004-8/2008, Mount Sinai School of Medicine, New York, NY

Assistant Professor – Radiation Oncology Department

6/2005-8/2008, James J. Peters VA Medical Center, Bronx, NY

Attending - Radiation Oncology Department

8/2008-8/2011, Florida Radiation Oncology Group, Jacksonville, FL

Private Practice Employee – Radiation Oncology

8/2011-4/2012, Florida Cancer Physicians Specialists, Tampa, FL

Private Practice-Director of South Florida Cancer Centers

4/2014-4/2016, Bay Pines VA Medical Center, St. Petersburg, FL

Part-Time Attending – Radiation Oncology Department

4/2012-Present, Florida Physicians Specialists/ Terk Oncology, Jacksonville, FL

Private Practice – Partner

Education

Columbia College, Columbia University, 8/1989-7/1993

General Studies, Columbia University, 8/1993-7/1995

State University of New York at Stony Brook School of Medicine, 8/1995-7/1999

Mount Sinai School of Medicine, NY, 8/2004-7/2006

Masters of Science degree in Clinical Research

Training Programs

8/1999-7/2000, St. Lukes-Roosevelt Hospital, NY

Internship – Internal Medicine

8/2000-7/2004, Mount Sinai School of Medicine, NY

Residency – Radiation Oncology

Chief Resident – 2003/04

Professional Academic Appointments

Research Assistant 7/1993 – 6/1995 Department of Pathology, College of Physicians & Surgeons, Columbia University, New York, New York

Board Member, Written and Oral Board 03 – Genitourinary Cancers. American Board of Radiology, Initial Certification Exam and Maintenance of Certification Examination three-year term 10/15/ 2018-2023.

Certification

Board Certification, American Board of Radiology, Radiation Oncology, 6/2006 and recertification 10/2015.

Licensure

11/28/2001, New York, 223361

7/22/2008, Florida, ME102354

Honors/ Awards/ Patents

Spinal shield implant and treatment of spinal metastases, US patent number US 20120037165 A1 also published as WO 2010033756 A2 and WO2010033756 A3 with Arthur Jenkins, MD, Department of Neurosurgery, Mount Sinai Hospital, NY, NY.

Patient's Choice Award, Vitals.com, 2016, 2015, 2014, 2013, 2012, 2011, 2010

Best Doctors in America Award, 2021, 2020, 2019,2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010

Jacksonville Magazine's Best Doctors 2021, 2020, 2019, 2018, 2017, 2016, 2015

Orlando Magazine's Best Doctor Award, 2014, 2013, 2012

Orlando Life Magazine's Top Doctors Award, 2014

Orlando Style Magazine's Elite Doctors Award, 2014

Administrative Leadership Appointments

Alumni Committee Member, 5/1995 – Present, Columbia University, New York, NY

Admissions Committee Member, 5/1997 – Present, Columbia University, New York, NY

Member, 7/2004-7/2008, Mount Sinai Hospital, Continuing Education Committee, New York, NY

Member, 7/2004-7/2008, Medical Director Committee of the Mount Sinai Faculty Practice, New York, NY

Associate Member, 7/2005-7/2013, Children's Oncology Group, Monrovia, CA

Member, 7/2006 – 7/2011, Annual Meeting Subcommittee, American Society of Therapeutic Radiation Oncology, Fairfax, VA

Vice Chairman, 7/2007-7/2008, New York Roentgen Society, New York, NY

Course Director, Contemporary Management of Prostate Cancer. Jacksonville, Florida. Inaugural international meeting. February 21, 2009.

Alumni Committee Member, 10/2010-Present, Stony Brook School of Medicine, New York, NY

Course Director, Contemporary Management of Prostate Cancer. Ponte Vedra Beach, Florida. Second annual international meeting. February 12, 2011

Course Director, Contemporary Management of Prostate Cancer. Orlando, Florida. Third annual international meeting. March 24, 2012

Medical Director, 7/2013 – 12/2013, Prologics, LLC, Franklin, TN

Consultant, 7/2004- 12/2014, Bard Urological, Covington, Georgia

Consultant, 7/2005 –12/2014, Medicon, Osaka, Japan

Course Director, Contemporary Management of Prostate Cancer. NY, NY. Fourth annual international meeting. April 13, 2013

Course Director, Contemporary Management of Prostate Cancer. Malibu, CA. Fifth annual international meeting. February 21, 2014

Grants and Contract Support and Ongoing studies:

Project entitled, "Genome-Wide Association Study to Identify SNPs and CNPs Associated with Development of Radiation Injury in Prostate Cancer Patients Treated with Radiotherapy."

Sponsor: Department of the Army, Prostate Cancer Research Program PC07201 Co-Principle Investigators: Rosenstein BA, Ostrer H. Co-Investigator: Cesaretti JA (7/1/05-6/30/08)

Project entitled, "ATM Heterozygosity and the Development of Radiation-Induced Erectile Dysfunction and Urinary Morbidity Following Radiotherapy for Prostate Cancer." Sponsor: National Institute of Health Loan Repayment Program Principle Investigator: Cesaretti JA Total award, \$65,920 over 2 years (7/1/05-6/30/07)

Project entitled, "Genetic Predictors of Adverse Radiotherapy Response in African-Americans." Sponsor: American Cancer Society Principle Investigator: Rosenstein BA Co-Investigator: Cesaretti JA Total award, \$840,000 over 4 years (7/1/05-6/30/09)

Basic Science Travel Grant, Cesaretti JA ASTRO Research Evaluation Committee ASTRO's 46th Annual Meeting in Atlanta, GA from October 3-7, 2004

Project entitled, "ATM Heterozygosity and the Development of Radiation-Induced Erectile Dysfunction and Urinary Morbidity Following Radiotherapy for Prostate Cancer." Physician Research Training Award, PCO31163, 2003, Prostate Cancer Research Program. Sponsor: Department of Defense. Principle Investigator: Cesaretti JA Mentors: Stock RG, Rosenstein BA Total award, \$700,000 over 5 years (7/1/04-6/30/09)

Phase III Study: High Dose Radiation Therapy with or without Androgen Suppression for Intermediate and Favorable High-Risk Adenocarcinoma of the Prostate. In house study approved by Baptist Medical Center IRB 8/2013 – 8/2015.

Observational Study: Outcomes of Men Treated with Radiation Therapy, Brachytherapy or Both for the Cure of Prostate Cancer. In house study approved by Baptist Medical Center IRB #10-20 FPS.

Genetic Repository Ongoing Study: Genetic Factors Associated with the Development of Normal Tissue Toxicities Following Radiotherapy for Prostate Cancer. In collaboration with Mount Sinai Hospital approved locally through the Baptist Medical Center IRB #09-30, FPS.

Teaching Activities:

Database analysis and reporting of 410 Gleason 9-10 Prostate Cancer Patients treated with Hormone therapy, Radiation therapy and Brachytherapy. Independent Study advisor to Erica Forbes, Medical Student, January 2022 – Ongoing.

Cesaretti J. 2018 ABS-MDAnderson Winter Prostate Brachytherapy School. Proctorship for Low Dose Rate Brachytherapy School. November 30-December 2, 2018

Influence of stigma on quality of life for prostate cancer patients and their romantic partners. Collaboration with Andrew Wood, PhD Candidate, University of Central Florida. 5/2010 – present.

Residency instructor for Mayo Clinic Jacksonville, 8/2008-8/2011, Baptist Hospital, Jacksonville, FL

Publications

Cesaretti JA, Stone NN, Stock RG “Late exacerbation of urinary symptoms following I-125 prostate brachytherapy” *International Journal of Radiation Oncology*Biology*Physics*, Volume 54, Issue 2, Supplement 1, 1 October 2002, Page 45

Cesaretti JA, Stone NN, Stock RG. “Urinary symptom flare following I-125 prostate brachytherapy.” *Int J Radiat Oncol Biol Phys* 2003 Jul 15; 56(4):1085-92.

Stock RG, Stone NN, Cesaretti JA. "Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications." *Int J Radiat Oncol Biol Phys* 2003 Jun 1; 56(2):448-53.

Dosoretz AM, Stock RG, Cesaretti JA, Stone NN "Role of external beam radiation and hormonal therapy in low, intermediate, and high risk patients treated with permanent radioactive seed implantation" *International Journal of Radiation Oncology*Biology*Physics*, Volume 57, Issue 2, Supplement 1, 1 October 2003, Page S227

Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. "Combined Modality Treatment in the Management of High Risk Prostate Cancer." *Int J Radiat Oncol Biol Phys* 2004 Aug 1; 59(5):1352-1359.

Marshall DT, Stone NN, Stone JJ, Cesaretti JA, Stock RG "Hormonal therapy reduces the risk of post-implant urinary retention in symptomatic prostate cancer patients with glands larger than 50 cc" *International Journal of Radiation Oncology*Biology*Physics*, Volume 60, 1, Supplement 1, September 2004, Pages S451-S451

Cesaretti JA, Stock RG, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Sheryl S, Loeb K, Kollmeier M, Smith M, et al. "ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer" *International Journal of Radiation Oncology*Biology*Physics*, Volume 60, 1, Supplement 1, September 2004, Pages S325-S325

Stock RG, Stone NN, Cesaretti JA "Does local control impact prostate cancer specific survival (PCSS) within the first 10 years following brachytherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 60, 1, Supplement 1, September 2004, Pages S184-S184

Rosenstein BS, Andreassen CN, Alsner J, Overgaard JM, Cesaretti JA, Atencio DA, Green S, Formenti SC, Stock RG, Overgaard J "ATM sequence variants and adverse radiotherapy response in breast cancer patients" *International Journal of Radiation Oncology*Biology*Physics*, Volume 60, 1, Supplement 1, September 2004, Pages S207-S208

Cesaretti JA, Stone NN, Stock RG. "Does a prior transurethral resection of the prostate compromise brachytherapy quality: a dosimetric analysis." *Int J Radiat Oncol Biol Phys*. 2004 Oct 1; 60(2):648-653.

Cesaretti JA, Stock RG, Atencio DA, Bernstein J, Stone NN, Wallenstein S, Green S, Loeb KL, Kollmeier MA, Smith M, Rosenstein BS. "ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer." *Int J Radiat Oncol Biol Phys*. 2005 Jan 1;61(1):196-202.

Cesaretti JA, Stock RG, Stone NN. "Brachytherapy." Book Chapter, Prostate Cancer: Principles and Practice, Ed by Kirby R, Partin AW, Feneley M, Parsons JK. Taylor and Francis Medical Books.

Kollmeier MA, Stock RG, Cesaretti JA, Stone NN. "Urinary Morbidity Following Post-brachytherapy Transurethral Resection of the Prostate." *J Urol*. 2005 Mar;173(3):808-12.

Cesaretti JA, Stone NN, Stock RG "Impact of Low Dose Rate Prostate Brachytherapy on the Sexual Health of Men with Normal Pre-treatment Sexual Function; an Analysis at Seven-years Minimum Follow-up" *International Journal of Radiation Oncology*Biology*Physics*, Volume 63, Supplement 1, 1 October 2005, Pages S80-S81

Zagar TM, Stone NN, Cesaretti JA, Stock RG "Assessment of Post-Brachytherapy Sexual Function: A Comparison of the IIEF-5 and the MSEFS" • ABSTRACT *International Journal of Radiation Oncology*Biology*Physics*, Volume 63, Supplement 1, 1 October 2005, Page S189

Stock RG, Stone NN, Cesaretti JA, Rosenstein BS "Biologically Effective Dose Values for Prostate Brachytherapy: Effects on PSA Failure and Post-Treatment Biopsy Results" *International Journal of Radiation Oncology*Biology*Physics*, Volume 63, Supplement 1, 1 October 2005, Page S292

Ho AY, Atencio DP, Fan G, Green S, Formenti SC, Haffty BG, Bernstein JL, Iyengar P, Stock RG, Cesaretti JA, et al. "ATM Sequence Variants as Predictors for Late Normal Tissue Responses in Breast Cancer Patients Treated with Radiotherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 63, Supplement 1, 1 October 2005, Pages S457-S458

Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA et al. "ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy." *Int J Radiat Oncol Biol Phys*. 2006 Mar 1;64(3):776-83.

Stock RG, Cesaretti JA, Stone NN. "Disease-specific survival following the brachytherapy management of prostate cancer." *Int J Radiat Oncol Biol Phys*. 2006 Mar 1;64(3):810-6.

Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green S, Formenti SC, Stock RG, Rosenstein BS. "ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy." *Int J Radiat Oncol Biol Phys*. 2006 Mar 1;64(3):776-83.

Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. "Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and post-treatment biopsy results." *Int J Radiat Oncol Biol Phys*. 2006 Feb 1;64(2):527-33.

Stock RG, Ho A, Cesaretti JA, Stone NN. "Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control." *Int J Radiat Oncol Biol Phys*. 2006 Oct 1;66(2):389-94.

Cesaretti JA, Stock RG, Atencio DP, Peters SR, Stone NN, Peters CA, Burri RJ, Fan G, Rosenstein BS : "A Genetically Determined Dose Volume Histogram Predicts for Rectal Bleeding Among Patients Treated With Prostate Brachytherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S37

Stock RG, Cesaretti JA, Stone NN "Patterns of Failure Following the Brachytherapy Management of Prostate Cancer" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S58

Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters SR, Burri RJ, Stone NN, Rosenstein BS "TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S69

Burri RJ, Stock RG, Atencio DP, Peters SR, Cesaretti JA, Peters CA, Fan G, Stone NN, Rosenstein BS "Single Nucleotide Polymorphisms in SOD2 and XRCC1 Correlate With the Development of Late Normal Tissue Toxicities in Prostate Cancer Patients Treated With Radiotherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S99

Kao J, Cesaretti JA, Dumane V, Stone NN, Stock RG "Improving the Therapeutic Ratio of Prostate Brachytherapy: Dose Escalation in I-125 Prostate Implants" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S323

Ho AY, Cesaretti JA, Stone NN, Stock RG "Radiation Dose, Not Treatment Regimen, Is the Most Significant Predictor of Biochemical Control in Patients With Intermediate Risk Prostate Cancer" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S348

Terk M, Lo K, Cesaretti JA, Stone NN, Stock RG "Salvage Pd-103 Seed Implantation in the Treatment of Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiation Therapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S361

Park JL, Cesaretti JA, Kao J, Stone NN, Stock RG "Vardenafil Is More Efficacious Than Tadalafil for Patient's who Requested an Alternative To Sildenafil Following Prostate

Brachytherapy”*International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S540

Rosenstein BS, Stock RG, Atencio DP, Cesaretti JA, Stone NN, Peters SR “Use of the Surveyor Nuclease Assay to Identify Genetic Variants Predictive for the Development of Adverse Radiotherapy Effects” *International Journal of Radiation Oncology*Biology*Physics*, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S584

Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. “Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.” *Int J Radiat Oncol Biol Phys*. 2006 Jul 1;65(3):646-55.

Peters CA, Cesaretti JA, Stone NN, Stock RG. “Brachytherapy for patients with inflammatory bowel disease.” *Int J Radiat Oncol Biol Phys*. 2006 Oct 1;66(2):424-9.

Lehrer S, Cesaretti JA, Stone NN, Stock RG. “Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.” *BJU Int*. 2006 Nov;98(5):979-81.

Schiff JD, Bar-Chama N, Cesaretti JA, Stock R. “Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.” *BJU Int*. 2006 Dec;98(6):1255-8.

Zagar TM, Stock RG, Cesaretti JA, Stone NN. “Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS.” *Brachytherapy*. 2007 Jan-Mar;6(1):26-33.

Ho AY, Burri RJ, Jennings GT, Stone NN, Cesaretti JA, Stock RG. “Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer.” *Brachytherapy*. 2007 Jan-Mar;6(1):38-43.

Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, Stone NN, Rosenstein BS. “A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.” *Int J Radiat Oncol Biol Phys*. 2007 May 8; [Epub ahead of print]

Ho AY, Fan G, Atencio DP, Green S, Formenti SC, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS. “Possession of ATM Sequence Variants as Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated with Radiotherapy.” *Int J Radiat Oncol Biol Phys*. 2007 May 19; [Epub ahead of print]

Cesaretti JA, Kao J, Stone NN, Stock RG. “Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at ≥ 7 years of follow-up.” *BJU Int*. 2007 Aug;100(2):362-7.

Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS. "TGFB1 Single Nucleotide Polymorphisms are Associated with Adverse Quality of Life in Prostate Cancer Patients Treated with Radiotherapy." *Int J Radiat Oncol Biol Phys*. 2007 Aug 7; [Epub ahead of print]

Cesaretti JA, Stone NN, Skouteris BM, Park JL, Stock RG. "Brachytherapy for Prostate Cancer." *Cancer J*. 2007 Sep-Oct;13(5):302-12.

Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG. "(125)I monotherapy using D90 implant doses of 180 Gy or greater." *Int J Radiat Oncol Biol Phys*. 2007 Oct 31; [Epub ahead of print]

Cesaretti JA, Stock RG, Stone NN and Rosenstein BS "Combined Low Dose Rate Brachytherapy and External Beam Radiotherapy Result in a Favorable Acute Urinary Symptom Profile Relative to Brachytherapy Monotherapy at the Same Biological Equivalent Dose (BED)" *International Journal of Radiation Oncology*Biology*Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Page S630

Peters CA, Stone NN, Cesaretti JA and Stock RG "The Effect of Family History on Outcome in Patients Treated With Low-Dose Rate Brachytherapy for Clinically Localized Prostate Cancer" *International Journal of Radiation Oncology*Biology*Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Pages S370-S371

Solan AN, Stock RG, Cesaretti JA and Stone NN "Correlation Between Erectile Dysfunction and Dose to Penile Bulb and Neurovascular Bundles Following Prostate Brachytherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Pages S351-S352

Skouteris VM, Stone NN, Stock RG and Cesaretti JA "Dose Response Study of Pd-103 Prostate Seed Implantation" *International Journal of Radiation Oncology*Biology* Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Pages S349-S350

Stock RG, Cesaretti JA and Stone NN "Comparisons of PSA Failure Definitions Following Trimodality Therapy for Intermediate to High-Risk Prostate Cancer" *International Journal of Radiation Oncology*Biology*Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Pages S344-S345

Klein TJ, Stock RG, Cesaretti JA and Stone NN "Prognostic Significance of the 5-Year PSA Value for Predicting Prostate Cancer Recurrence Following Brachytherapy" *International Journal of Radiation Oncology*Biology*Physics*, Volume 69, Issue 3, Supplement 1, 1 November 2007, Pages S176-S177

Ho AY, Fan G, Cesaretti JA, Stone NN and Stock RG "Young Men have Equivalent Biochemical Outcomes Compared to Older Men After Treatment With Prostate Brachytherapy" *International*

Journal of Radiation Oncology*Biology*Physics, Volume 69, Issue 3, Supplement 1, 1
November 2007, Pages S90-S91

Fan G, Skouteris B, Stone NN, Stock RG and Cesaretti JA “Impact of Prostate Volume as a Predictor of Urinary Incontinence Following Radioactive Seed Implantation for Prostate Cancer” International Journal of Radiation Oncology*Biology*Physics, Volume 69, Issue 3, Supplement 1, 1 November 2007, Page S31

Rosenstein BS, Cesaretti JA, Stock RG, Stone NN, Atencio DP, Peters CA, Burri R and Peters S “A Validation Study to Examine the Correlation Between Possession of Variants in the ATM Gene With the Development of Erectile Dysfunction in Prostate Cancer Patients Treated With Radiotherapy” International Journal of Radiation Oncology*Biology*Physics, Volume 69, Issue 3, Supplement 1, 1 November 2007, Page S29

Moore J., Stock RG, Cesaretti JA, Stone NN, Li W, Peters S, Atencio DP, Peters CA, Burri R and Rosenstein BS “Single Nucleotide Polymorphisms as Predictors for Development of Erectile Dysfunction in African-American Men Treated With Radiotherapy for Prostate Cancer” International Journal of Radiation Oncology*Biology*Physics, Volume 69, Issue 3, Supplement 1, 1 November 2007, Page S7

Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. “Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma” Cancer. 2007 Dec 12; [Epub ahead of print]

Cesaretti J, Pennather A, Rosenstein B, Swanson S, Fernando H. “Radiosurgery for Thoracic Malignancies.” Ann Thorac Surg. 2008 Feb;85(2):S785-91

Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS. “Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.” Radiat Res. 2008 Jul;170(1):49-59

Stock RG, Cesaretti JA, Unger P, Stone NN. “Distant and local recurrence in patients with biochemical failure after prostate brachytherapy.” Brachytherapy. 2008 Jul-Sep;7(3):217-22.

Solan AN, Cesaretti JA, Stone NN, Stock RG. “There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.” Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1468-74.. Epub 2008 Oct 14.

Stock RG, Klein TJ, Cesaretti JA, Stone NN. “Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.” Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. Epub 2008 Dec 10.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. "Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy." *Int J Radiat Oncol Biol Phys*. 2009 Sep 1;75(1):16-22. Epub 2009 Mar 14.

Stock RG, Cesaretti JA, Hall SJ, Stone NN. "Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy." *BJU Int*. 2009 Dec;104(11):1631-6.. Epub 2009 Jun 2.

Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. "Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response." *Cancer*. 2009 Aug 1;115(15):3571-80. Erratum in: *Cancer*. 2011 Jun 15;117(12):2826.

Stone NN, Stock RG, Cesaretti JA, Unger P. "Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes." *Int J Radiat Oncol Biol Phys*. 2010 Feb 1;76(2):355-60. Epub 2009 Jul 23.

Goldsmith B, Cesaretti J, Wisnivesky JP. "Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the Elderly." *Cancer*. 2009 Oct 15;115(20):4865-4873.

Stone NN, Cesaretti JA, Rosenstein B, Stock RG. "Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?" *Brachytherapy*. 2010 Apr-Jun;9(2):114-8. Epub 2009 Oct 30.

Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. "Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?" *J Urol*. 2010 Feb;183(2):634-9. Epub 2009 Dec 16

Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG. "Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer." *Int J Radiat Oncol Biol Phys*. 2010 Aug 1;77(5):1315-21. Epub 2010 Jan 13.

Park CH, Bonomi M, Cesaretti J, Neugut AI, Wisnivesky JP. "Effect of radiotherapy planning complexity on survival of elderly patients with unresected localized lung cancer." *Int J Radiat Oncol Biol Phys*. 2011 Nov 1;81(3):706-11. Epub 2010 Oct 6.

The Role of MRI in Radiation Therapy Planning. Published 2011 Siemens Medical Solutions, USA

Kao J, Cesaretti JA, Stone NN, Stock RG. "Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity." *Curr Urol Rep*. 2011 Jun;12(3):237-42.

Diefenbach MA, Mohamed NE, Butz BP, Bar-Chama N, Stock R, Cesaretti J, Hassan W, Samadi D, Hall SJ. "Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study." *J Med Internet Res*. 2012 Jan 13;14(1):e6.

Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. "Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases." *PLoS One*. 2012;7(6):e36979. Epub 2012 Jun 27.

Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruyscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS. "A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer." *Int J Radiat Oncol Biol Phys*. 2013 Jan 1;85(1):e21-8. Epub 2012 Sep 26.

Vargas C, Swartz D, Vashi A, Blasser M, Kasareian A, Cesaretti J, Kiley K, Terk M. "Long-term outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy." *Brachytherapy*. 2013 Mar-Apr;12(2):120-5. Epub 2012 Oct 10.

Kerns SL, Stock RG, Stone NN, Blacksburn SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruyscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H. "Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer." *Radiother Oncol*. 2013 May 26

Vargas C, Swartz D, Vashi A, Blasser M, Cesaretti J, Kiley K, Koziol J, Terk M. Salvage Brachytherapy for recurrent prostate cancer. *Brachytherapy* 2014 Jan-Feb;13(1):53-8.

Cesaretti, JA, Terk M. External Beam Radiation and Proton Therapy for Prostate Cancer. *Northeast Florida Medicine*. 2014; 65 (4) 37-44.

Cesaretti JA, Terk M. The Modern Radioactive Seed Implant for Prostate Cancer Treatment. *Northeast Florida Medicine*. 2014; 65 (4) 45-53.

Hobbs C, Cesaretti J, Terk M et al. Radiation Oncology is an Essential Component of Effective Palliative Care for Patients with Cancer. *Northeast Florida Medicine*. 2016; 67 (1) 19-25.

Cesaretti JA, Terk M, Olsen M et al. Modern Palliative Radiation Therapy. *Northeast Florida Medicine*. 2016; 67 (1) 23-27.

Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruyscher D, Cesaretti JA, et al. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiother Oncol*. 2016 Dec;121(3):431-439.

Wood AW, Barden S, Terk M, Cesaretti J. The influence of stigma on the quality of life for prostate cancer survivors. *J Psychosoc Oncol*. 2017 Jul-Aug;35(4):451-467

Wood A, Barden S, Terk M, Cesaretti J. Prostate cancer: the influence of stigma on quality of life and relationship satisfaction for survivors and their partners. *J Psychosoc Oncol*. 2018 Dec 22:1-17.

Vargas C, Alam N, Terk M, Niska J, Cesaretti J, et al. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer. *Cancer Treat Res Commun.* 2019;19:100119.

Smith WH, Cesaretti J, Chin CP, Terk M, Stock RG. Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy. *Radiother Oncol.* 2020 Oct 17;155:42-47.

Lectures/Presentations/Abstracts/Teaching/Book Chapters:

Cesaretti JA, Stone NN, Stock RG. “Late Exacerbation of Urinary Symptoms Following I-125 Prostate Brachytherapy.” ASTRO 44th Annual Meeting, October 2002, New Orleans, Louisiana.

Cesaretti JA, Atencio DA, Stock RG, Stone NN, Green S, Bernstein JL, Wallenstein S, Loeb K, Chalon O, Kollmeier MA, Smith MJ, Rosenstein BA. “ATM Mutational Status is Associated with an Increased Severity and Earlier Onset of Radiation-Related Rectal Morbidity Among Patients Treated with 125I Prostate Brachytherapy.” RSNA 89th Annual Meeting, November 2003, New York, New York.

Cesaretti JA. “Interactive Ultrasound Guided Prostate Brachytherapy; The Mount Sinai Experience.” First Annual Radiation Oncology Symposium, Galliera Hospital, November 2003, Genoa, Italy.

Cesaretti JA. “Real Time Brachytherapy: The American Experience.” International Course on Brachytherapy, San Paolo Hospital, February 2004, Savona, Italy.

Cesaretti JA. “Genetic Associations Are Predictive Of Adverse Outcomes Following Radiotherapy For Prostate Cancer.” Radiological and Medical Physics Society of New York (RAMPS), Spring Symposium Advancing Radiation Oncology Planning Through an Understanding of Biology, May 2004, New York, New York.

Cesaretti JA. “ATM Sequence Variants are Predictive of Adverse Radiotherapy Response Among Patients Treated for Prostate Cancer.” ASTRO 46th Annual Meeting, October 2004, Atlanta, Georgia.

Cesaretti JA. “Intensity Modulated Radiation Therapy for Brain Malignancies.” IV Advanced Techniques and Technology in Image-Guided Brain and Spine Surgery, December 5, 2004, New York, New York.

Cesaretti JA. “Radiation Therapy for Esophageal Carcinoma.” From Gastroesophageal Reflux Disease to Esophageal Cancer: New Treatments and Technologies, April 2, 2005, The New York Academy of Medicine, New York, New York.

Cesaretti JA. “Intensity Modulated Radiation Therapy for Prostate Cancer” and “Combined Modality Therapy for Prostate Cancer.” Advanced Workshop in the Treatment of Prostate Cancer, April 27-29, 2005, The New York Academy of Medicine, New York, New York.

Cesaretti JA. “Intensity Modulated Radiation Therapy for Prostate Cancer” and “Combined Modality Therapy for Prostate Cancer.” Advanced Workshop in the Treatment of Prostate Cancer II, September 27-29, 2005, The New York Academy of Medicine, New York, New York.

Cesaretti JA. “Erectile function following prostate brachytherapy with 7 years minimum follow-up.” ASTRO 47th Annual meeting, October 2005, Denver, Colorado.

Cesaretti JA. “The Genetics of Radiation Sensitivity.” 11th Annual Scottsdale Prostate Cancer Symposium, March 1-5, 2006, Scottsdale, Arizona.

Terk M, Lo K, Cesaretti J, Stone N, Stock R. Salvage Pd-103 seed implantation in the treatment of locally recurrent prostate cancer previously treated with external beam radiation therapy. Proc ASTRO, International Journal of Radiation Oncology Biology Physics 2006; 66(3): s361

Cesaretti JA. “A dose volume histogram for the incidence of rectal bleeding among ATM heterozygotes.” ASTRO 48th Annual meeting, November 2006, Philadelphia, Pennsylvania.

Cesaretti JA. “Loose versus Stranded seeds.” “Genetic Predictors of Radiotherapy Response.” “Salvage Brachytherapy.” 12th Annual Scottsdale Prostate Cancer Symposium, March 1-4, 2007, Scottsdale, Arizona.

Cesaretti JA. “Prostate Brachytherapy, the Mount Sinai Experience.” 95th Annual Japanese Urological Association meeting, April 14th 2007, Osaka, Japan.

Cesaretti JA. “Intensity Modulated Radiation Therapy for Prostate Cancer” and “Combined Modality Therapy for Prostate Cancer.” Advanced Workshop in the Treatment of Prostate Cancer II, April 25-27, 2007, The New York Academy of Medicine, New York, New York.

Cesaretti JA. “Stereotactic Radiosurgery for Lung Cancer.” 1st Annual Minimally Invasive Thoracic Surgery Summit, June 6th 2007, New York, New York.

Ivanova, I. “High Deductibles have Patients Clamoring for Cost Clarity” Crain’s New York Business. 10/7/2007.

Cesaretti JA. “Single Nucleotide Polymorphisms as Predictors for Development of Erectile Dysfunction in African-American Men Treated With Radiotherapy for Prostate Cancer.” ASTRO 49th Annual meeting, November 2007, Los Angeles, California.

Cesaretti JA. “Brachytherapy for Prostate Cancer.” New York Roentgen Society, November 2007, New York, New York.

Cesaretti JA, Stone NN, Kao J, Stock RG. Book chapter “Brachytherapy for prostate cancer” in Treatment Methods for Early and Advanced Prostate Cancer. Kirby RS, Partin A, Parsons JK, Feneley M. Johns Hopkins University press 05/2008.

Cesaretti JA. “Innovations in Prostate Brachytherapy.” 4th International Interstitial Prostate Brachytherapy Teaching Course, January 2008, Bergisch-Gladbach, Germany.

Cesaretti JA. “Brachytherapy into the Future.” CR BARD Urological National Sales Meeting Keynote address, January 2008, Atlanta, Georgia.

Terk M, Cesaretti J, Nurani R, Hixson R, Swartz D, Blasser M. Long-term prostate brachytherapy outcomes with 10 years of minimum follow-up. International Journal of Radiation Oncology Biology Physics. 1 November 2009 (Vol. 75, Issue 3, Supplement, Page S155)

Cesaretti J, Nurani R, Hixson R, Swartz D, Blasser M, Terk M. Identification of Optimal Patients for Salvage Prostate Seed Implantation in the Treatment of Locally Recurrent Cancer Previously Treated with External Radiation Therapy. International Journal of Radiation Oncology Biology Physics. 1 November 2009 (Vol. 75, Issue 3, Supplement, Page S157)

Simmons D, Cesaretti J, Nurani R, Hixson R, Paryani J, Jhamnani R, Terk M. Adoption of evolving intra-operative treatment planning software has resulted in improved post-operative prostate seed implant dosimetry. International Journal of Radiation Oncology Biology Physics. 1 November 2009 (Vol. 75, Issue 3, Supplement, Pages S341-S342)

Hixson R, Nurani R, Cesaretti J, Paryani J, Jhamnani R, Terk M. Use of an intra-operative dosimetry technique accurately predicts 1 month post-implant dosimetry. International Journal of Radiation Oncology Biology Physics. 1 November 2009 (Vol. 75, Issue 3, Supplement, Page S305)

Nurani R, Cesaretti J, Hixson R, Vashi A, Kasraeian A, Terk M. Long-term biochemical control and survival in high-risk prostate cancer patients treated with seed implant-based therapy. International Journal of Radiation Oncology Biology Physics. 1 November 2009 (Vol. 75, Issue 3, Supplement, Pages S154-S155)

Swartz D, Terk M, Vashi A, Cesaretti J, Hixson R, Nurani R. Brachytherapy for localized prostate cancer: outcome results with 10-years minimum follow-up. The Journal of Urology April 2010 (Vol. 183, Issue 4, Supplement, Page e675)

Nurani R, Terk M, Cesaretti J, Hixson R, Vashi A, Swartz D. 10 Year outcomes for clinically localized high risk prostate cancer treated with combination palladium brachytherapy, low dose external radiation therapy, and short course hormonal ablation therapy. Presentation at Southeast Section of the American Urological Association Annual Meeting, Miami, Florida, March 2010

Cesaretti J, Nurani R, Hixson R, Terk M, Vashi A, Swartz D. Salvage Prostate Brachytherapy for Primary External Beam Radiation Therapy Failures. Presentation at Southeast Section of the American Urological Association Annual Meeting, Miami, Florida, March 2010

Cesaretti, JA. “Treatment Planning for Pd-103 [Activity/volume and Nomograms].” The University of Texas MD Anderson Cancer Center conference entitled, “The Process of Quality Assurance in Prostate Brachytherapy,” December 3-4, 2011, Houston, TX.

Cesaretti JA. Program speaker at Biennial National Congress of the SA Society of Clinical & Radiation Oncology (SASCRO) & the SA Society of Medical Oncology (SASMO), 24 – 27 August 2011 at the Sun City Resort, South Africa.

Burri R, Ng J, Horowitz D, Cesaretti J, Terk M et al. Rectal balloons and the risk of secondary rectal cancer after combined modality prostate radiation. World Congress of Brachytherapy 2012, Barcelona, Spain, May 10-12, 2012

Cesaretti JA. Program speaker at the annual international prostate cancer conference. March 24, 2012, Orlando, FL.

Cesaretti JA. Invited to speak at Health 2.0's Spring Fling conference in Boston about his work with Internet Marketing. The Spring Fling Conference will be held May 14 - 15, 2012, Boston, MA.

Cesaretti JA. Guest speaker on Prostate Cancer Treatment at the 2012 Instituto de Educacao Medica Conference on June 29th & 30th in Campo Grande, Lisbon, Portugal.

Cesaretti, JA. Program Speaker at the Prostate Cancer Symposium. March 7-10m 2013, Phoenix, AZ.

Cesaretti JA. "How Digital is putting the Patient in the Driver's Seat." 17th Annual Greystone.net 2013 Healthcare Internet Conference October 21, 2013, New Orleans, LA.

Cesaretti JA. Program speaker at the annual international prostate cancer conference. April 13, 2013, New York, NY.

Terk M, Vargas C, Cesaretti J, Swartz D, Blasser M, Vashi A, Kasraeian A, Koziol J, Kiley K. Excellent long-term outcomes with prostate brachytherapy in young men less than 55 years old. Brachytherapy. 2013; 12 (2), Suppl 1, S12

Cesaretti JA. "State of the Art Prostate Brachytherapy" 2014 Annual Florida Radiological Society & FRBMA's Meeting July 11-13, 2014 Ritz Carlton Orlando, Florida.

Cesaretti JA. "Advanced Radiation Technology for Prostate Cancer" 2014 Annual Florida Radiological Society & FRBMA's Meeting July 11-13, 2014 Ritz Carlton Orlando, Florida.

Kasraeian A, Cesaretti J, Yellin J, Noell B, Kasraeian A. Targeted MRI/US Fusion Prostate Biopsy: The First 206 Patients – A Single Urologist's Experience in a Small Private Community Urology Practice. Poster. Society of Urologic Oncology. Austin, Texas. November, 2016.

Kasraeian A, Cesaretti J, Yellin J, Noell B, Kasraeian A. Targeted MRI/US Fusion Prostate Biopsy: The First 206 Patients – A Single Urologist's Experience in a Small Private Community Urology Practice. Poster. World Congress of Endourology. Cape Town, South Africa. November, 2016.

Kasraeian A, Cesaretti J, Yellin J, Noell B, Kasraeian A. Targeted MRI/US Fusion Prostate Biopsy: The First 166 Patients Without a Prior History of Prostate Cancer – A Single Urologist's

Experience in a Small Private Community Urology Practice. Poster. World Congress of Endourology. Cape Town, South Africa. November, 2016.

Kasraeian A, Cesaretti J, Yellin J, Noell B, Kasraeian A. Targeted MRI/US Fusion Prostate Biopsy: The First 206 Patients – A Single Urologist’s Experience in a Small Private Community Urology Practice. Poster. Southeastern Section of the American Urological Association Annual Meeting. March, 2017.

Kasraeian A, Cesaretti J, Yellin J, Brochert, A, Noell B, Kasraeian A. Targeted MRI/US Fusion Prostate Biopsy: The First 212 Patients Without a History of Prostate Cancer - Relationship Between PIRADS Score and Prostate Cancer Detection Rate: A Single Urologist’s Experience. Poster (Accepted). World Congress of Endourology, Vancouver, Canada. September, 2017.

Cesaretti J, Terk M. Patients treated with Volumetric Modulated Arc Therapy for Prostate Cancer Return to Baseline Urinary Function Following Treatment to 81 Gy. Oral Presentation: Radiological Society of North America. November 28, 2017

Cesaretti J. “How to Prevent and Manage Urinary, Sexual and Rectal Toxicity”. Prostate Brachytherapy Conference. Mt Sinai School of Medicine, NY. November 3, 2018

Cesaretti J. “Brachytherapy in the Community” 2018 ABS-MDAnderson Winter Prostate Brachytherapy School. Bending the Slope of the Brachytherapy Curve by Building a High Quality Program. November 30-December 2, 2018.